Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy
Details
Publication Year 2024-03-01,Volume 109,Issue #3,Page 787-798
Journal Title
Haematologica
Publication Type
Research article
Abstract
T-cell-engaging bispecific antibodies (T-BsAb) have produced impressive clinical responses in patients with relapsed/refractory B-cell malignancies, although treatment failure remains a major clinical challenge. Growing evidence suggests that a complex interplay between immune cells and tumor cells is implicated in the mechanism of action and therefore, understanding immune regulatory mechanisms might provide a clue for how to improve the efficacy of T-BsAb therapy. Here, we investigated the functional impact of regulatory T (Treg) cells on anti-tumor immunity elicited by T-BsAb therapy. In a preclinical model of myeloma, the activation and expansion of Treg cells in the bone marrow were observed in response to anti-B-cell maturation antigen (BCMA) T-BsAb therapy. T-BsAb triggered the generation of induced Treg cells from human conventional CD4 cells after co-culture with tumor cells. Moreover, T-BsAb directly activated freshly isolated circulating Treg cells, leading to the production of interleukin-10 and inhibition of T-BsAb-mediated CD8 T-cell responses. The activation of Treg cells was also seen in bone marrow samples from myeloma patients after ex vivo treatment with T-BsAb, further supporting that T-BsAb have an impact on Treg homeostasis. Importantly, transient ablation of Treg cells in combination with T-BsAb therapy dramatically improved effector lymphocyte activities and disease control in the preclinical myeloma model, leading to prolonged survival. Together, this information suggests that therapy-induced activation of Treg cells critically regulates anti-tumor immunity elicited by T-BsAb therapy, with important implications for improving the efficacy of such treatment.
Publisher
Ferrata-Storti Foundation
Keywords
Humans; T-Lymphocytes, Regulatory; *Antibodies, Bispecific/pharmacology/therapeutic use; *Multiple Myeloma/drug therapy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes
Department(s)
Clinical Haematology
Open Access at Publisher's Site
https://doi.org/10.3324/haematol.2023.283758
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-04-02 01:32:28
Last Modified: 2024-04-02 01:32:43

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙